Literature DB >> 23008402

Percentage of acute stroke patients eligible for endovascular treatment.

Darin B Zahuranec1, Jennifer J Majersik.   

Abstract

Endovascular treatment for acute ischemic stroke has the potential to substantially improve the outcome for select individual stroke patients. However, the impact of this treatment on a population scale is unknown. We reviewed the epidemiology of acute stroke presentation times to estimate the proportion of patients with ischemic stroke who may be eligible for intra-arterial treatment. Experience with IV thrombolysis suggests that time from symptom onset is likely to be among the major exclusion criteria for intra-arterial treatment. Studies reviewed suggest that between 5% and 13% of patients with ischemic stroke present in the commonly recommended intra-arterial treatment window of 3 to 6 hours. Because of clinical exclusion factors other than time, the proportion of stroke patients eligible for intra-arterial treatment is likely even lower than these estimates. Clinicians and researchers should consider this a modest proportion of eligible patients when planning future studies and creating referral networks for endovascular stroke treatment.

Entities:  

Mesh:

Year:  2012        PMID: 23008402     DOI: 10.1212/WNL.0b013e31826957cf

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  8 in total

1.  White Matter Hyperintensity-Adjusted Critical Infarct Thresholds to Predict a Favorable 90-Day Outcome.

Authors:  Jatinder Patti; Johanna Helenius; Ajit S Puri; Nils Henninger
Journal:  Stroke       Date:  2016-09-15       Impact factor: 7.914

Review 2.  Inductive and Deductive Approaches to Acute Cell Injury.

Authors:  Donald J DeGracia; Fika Tri Anggraini; Doaa Taha Metwally Taha; Zhi-Feng Huang
Journal:  Int Sch Res Notices       Date:  2014-10-13

Review 3.  Improved clinical outcome 3 months after endovascular treatment, including thrombectomy, in patients with acute ischemic stroke: a meta-analysis.

Authors:  Anna Falk-Delgado; Åsa Kuntze Söderqvist; Jian Fransén; Alberto Falk-Delgado
Journal:  J Neurointerv Surg       Date:  2015-07-02       Impact factor: 5.836

Review 4.  Endovascular Recanalization Therapy in Acute Ischemic Stroke: Updated Meta-analysis of Randomized Controlled Trials.

Authors:  Keun-Sik Hong; Sang-Bae Ko; Ji Sung Lee; Kyung-Ho Yu; Joung-Ho Rha
Journal:  J Stroke       Date:  2015-09-30       Impact factor: 6.967

Review 5.  Efficacy and Safety of Cerebrolysin for Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Danfeng Zhang; Yan Dong; Ya Li; Jigang Chen; Junyu Wang; Lijun Hou
Journal:  Biomed Res Int       Date:  2017-06-05       Impact factor: 3.411

6.  Cerebrolysin for functional recovery in patients with acute ischemic stroke: a meta-analysis of randomized controlled trials.

Authors:  Zefeng Wang; Ligen Shi; Shenbin Xu; Jianmin Zhang
Journal:  Drug Des Devel Ther       Date:  2017-04-19       Impact factor: 4.162

7.  Neutrophil Extracellular Trap Targeting Protects Against Ischemic Damage After Fibrin-Rich Thrombotic Stroke Despite Non-Reperfusion.

Authors:  Carolina Peña-Martínez; Violeta Durán-Laforet; Alicia García-Culebras; María Isabel Cuartero; María Ángeles Moro; Ignacio Lizasoain
Journal:  Front Immunol       Date:  2022-02-16       Impact factor: 7.561

8.  Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial.

Authors:  Dafin F Muresanu; Wolf-Dieter Heiss; Volker Hoemberg; Ovidiu Bajenaru; Cristian Dinu Popescu; Johannes C Vester; Volker W Rahlfs; Edith Doppler; Dieter Meier; Herbert Moessler; Alla Guekht
Journal:  Stroke       Date:  2015-11-12       Impact factor: 7.914

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.